Table 4 Improved endurance performance and disease activity after 12 weeks of endurance exercise in myositis patients.
Patient | Group | MMT 0 to 80 | HAQ 0.00 to 3.00 | s-CPK μcat/l | Physician's global disease activity VAS 0 to 100 | Patient's global disease activity VAS 0 to 100 | Mitax 0.00 to 1.00 | Cycling time minutes | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EG/CG | 0w | 12w | 0w | 12w | 0w | 12w | 0w | 12w | 0w | 12w | 0w | 12w | 0w | 12w | |
A† | EG | 79 | 79 | 0.00 | 0.25 | 6.2 | 1.2 | 5 | 0 | 3 | 1 | 0.05 | 0.00 | 18 | 31‡ |
B† | EG | 70 | 75 | 0.50 | 0.38 | 2.2 | 1.9 | 4 | 0 | 72 | 5 | 0.11 | 0.07 | 8 | 55‡ |
C† | EG | 75 | 77 | 0.25 | 0.00 | 1.8 | 1.3 | 0 | 0 | 9 | 0 | 0.24 | 0.19 | 15 | 37‡ |
D† | EG | 76 | 80 | 0.38 | 0.00 | 4.2 | 2.3 | 0 | 0 | 0 | 9 | 0.10 | 0.06 | 25 | 30‡ |
E | EG | 42 | 57‡ | NA | 1.63 | 6.8 | 5.2 | NA | 3 | NA | 43 | 0.02 | 0.22 | 13 | 20‡ |
F† | EG | 76 | 75 | 0.50 | 0.50 | NA | NA | 14 | 0 | 15 | 0 | 0.16 | 0.04 | 15 | 50‡ |
G | EG | 71 | 76 | 0.38 | 0.38 | 1.5 | 2.0 | 3 | 0 | 32 | 11 | 0.00 | 0.00 | 10 | 15‡ |
H | EG | 76 | 78 | 0.50 | 0.50 | 1.0 | 1.1 | 11 | 7 | 54 | 53 | 0.06 | 0.02 | 20 | 40‡ |
I† | EG | 77 | 77 | 1.38 | 0.63 | 1.3 | 1.3 | 10 | 3 | 24 | 13 | 0.11 | 0.02 | 15 | 25‡ |
J | CG | 77 | 77 | 0.38 | 0.63 | 1.6 | 3.1 | 0 | 0 | 44 | 26 | 0.19 | 0.11 | 9 | 10 |
K† | CG | 72 | 74 | 0.38 | 0.00 | 1.8 | 1.8 | 1 | 0 | 13 | 5 | 0.06 | 0.10 | 15 | 15 |
L | CG | 66 | 73 | 0.50 | 0.13 | 1.3 | 1.2 | 0 | 0 | 77 | 52 | 0.09 | 0.21 | 15 | 15 |
M | CG | 75 | 70 | 0.50 | 0.38 | 3.7 | 1.9 | 3 | 5 | 20 | 44 | 0.14 | 0.13 | 20 | 20 |
N | CG | 57 | 75‡ | 1.75 | 2.00 | NA | NA | NA | 5 | 59 | 69 | NA | 0.24 | 8 | 8 |
O | CG | 75 | 72 | 0.63 | 0.88 | 1.2 | 1.6 | 10 | 6 | 39 | 59 | 0.13 | NA | 15 | 19‡ |